logo

For the Inventor, By the Inventor

Montreal, Canada

Rejean Fortin

This inventor holds 36 USPTO granted patents and 3 published patent applications, primarily in Leukotriene Inhibitors. Top assignees: Merck Frosst Canada, Inc., Merck Frosst Canada & Co., Merck + Co., Inc.. Active years: 1986-2012.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Rejean Fortin. Retrieved from https://idiyas.com/inventor/rejean-fortin

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 36 

% Patents Active = 86.1

Average Co-Inventor Count = 5.2

ph-index = 13

Forward Citations = 469(Granted Patents)


Location History:

  • Quebec, CA (1999 - 2000)
  • Montreal, CA (1986 - 2012)

Company Filing History:

goldMedal27 out of 212 
 
Merck Frosst Canada, Inc.
 patents
silverMedal6 out of 80 
 
Merck Frosst Canada & Co.
 patents
bronzeMedal3 out of 4,770 
 
Merck + Co., Inc.
 patents
4. 1 out of 2,405 
 
Merck Sharp + Dohme Corp.
 patents
where one patent can have more than one assignee

Years Active: 1986-2012

Loading Chart...
Areas of Expertise:
Leukotriene Biosynthesis
Cyclooxygenase Inhibitors
Heteroaromatic Compounds
Prostaglandin Receptor Ligands
Renin Inhibitors
Pyridine Derivatives
Phenothiazine Derivatives
Indole Derivatives
5-Lipoxygenase Activating Protein
Antiallergic Compositions
Selective Inhibitors
Pharmaceutical Compositions
36 patents (USPTO):Explore Patents
1. 8334308 - Renin inhibitors (2012-12-18),
2. 7799787 - Heteroaromatic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase (2010-09-21),
3. 7348433 - Quinolinones as prostaglandin receptor ligands (2008-03-25),
4. 7060715 - Substituted pyridines as selective cyclooxygenase-2 inhibitors (2006-06-13),
5. 6812346 - Substituted pyridines as selective cyclooxygenase-2 inhibitors (2004-11-02),
6. 6596736 - Substituted pyridines as selective cyclooxygenase-2 inhibitors (2003-07-22),
7. 6498151 - Aryldifluoromethylphosphonic acids with sulfur-containing substituents as PTP-1B inhibitors (2002-12-24),
8. 6071936 - Substituted pyridines as selective cyclooxygenase-2 inhibitors (2000-06-06),
9. 6046217 - 2,3,5-trisubstituted pyridines as inhibitors of cyclooxygenase-2 (2000-04-04),
10. 6001843 - Substituted pyridines as selective cyclooxygenase-2 inhibitors (1999-12-14),
11. 5932481 - Method for measuring metaplastic changes of mucus secreting epithelial (1999-08-03),
12. 5861419 - Substituted pyridines as selective cyclooxygenase-2 inhibitors (1999-01-19),
13. 5817700 - Bisaryl cyclobutenes derivatives as cyclooxygenase inhibitors (1998-10-06),
14. 5428060 - Heteroarylnaphthalene lactones as inhibitors of leukotriene biosynthesis (1995-06-27),
15. 5424320 - Heteroaryl coumarins as inhibitors of leukotriene biosynthesis (1995-06-13),

Title: The Innovative Journey of Rejean Fortin: Pioneering Cardiovascular and Metabolic Disease Treatments

Introduction:

Rejean Fortin, a prolific inventor hailing from Montreal, Canada, has left an indelible mark on the fields of cardiovascular and metabolic disease treatments. With an impressive portfolio of 36 patents to his name, Fortin continues to push the boundaries of medical innovation.

Latest Patents:

1. Renin Inhibitors: Fortin's groundbreaking invention focuses on biphenyl-based renin inhibitor compounds with amino-terminal groups. These compounds play a crucial role in treating cardiovascular events and renal insufficiency.

2. Heteroaromatic Compounds as Inhibitors of Stearoyl-Coenzyme A Delta-9 Desaturase: Fortin's invention of heteroaromatic compounds as selective inhibitors of SCD1 has immense potential in preventing and treating various conditions related to abnormal lipid synthesis and metabolism.

Career Highlights:

Fortin has gained invaluable experience and expertise through his tenure at Merck Frosst Canada, Inc. and Merck Frosst Canada & Co. His innovative spirit and dedication have significantly contributed to the advancement of medical science, particularly in the realm of cardiovascular and metabolic disease treatments.

Collaborations:

During his illustrious career, Fortin has closely collaborated with visionary individuals such as Daniel Dube and Yvan Guindon. Together, they have synergized their talents and insights to drive forward groundbreaking research and development initiatives in the healthcare sector.

Conclusion:

In conclusion, Rejean Fortin stands as a shining example of an inventor whose relentless pursuit of innovation has revolutionized the medical landscape. His pioneering work in cardiovascular and metabolic disease treatments continues to impact countless lives, cementing his legacy as a trailblazer in the field of medical science.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…